<?xml version="1.0" encoding="UTF-8"?>

<ResearchStudy xmlns="http://hl7.org/fhir">
  <id value="H2Q-MC-LZZT-ResearchStudy"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative</b></p><p><b>identifier</b>: id: H2Q-MC-LZZT (USUAL), id: NCTA12313212 (OFFICIAL), PLAC: NCTA12313212 (SECONDARY)</p><p><b>title</b>: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease</p><p><b>protocol</b>: <a href="PlanDefinition-LZZT-Study-Definition.html">Generated Summary: url: http://example.org/br-and-r/soa/PlanDefinition/LZZT-Study-Definition; version: 0.1.0; status: active; date: Apr 9, 2021, 11:42:58 AM</a></p><p><b>status</b>: completed</p><p><b>primaryPurposeType</b>: <span title="Codes: ">treatment</span></p><p><b>phase</b>: <span title="Codes: ">phase-3</span></p><p><b>category</b>: <span title="Codes: {http://ncimeta.nci.nih.gov C98388}">Interventional Study</span>, <span title="Codes: {http://ncimeta.nci.nih.gov C15417}">Randomized Clinical Trial</span>, <span title="Codes: {http://ncimeta.nci.nih.gov C15228}">Double Blind Study</span>, <span title="Codes: {http://ncimeta.nci.nih.gov C49648}">Placebo Control</span>, <span title="Codes: {http://ncimeta.nci.nih.gov C82639}">Parallel Study</span></p><p><b>focus</b>: <span title="Codes: {http://ncimeta.nci.nih.gov C152926}">Xanomeline</span>, <span title="Codes: {http://ncimeta.nci.nih.gov C149996}">Transdermal Patch Dosage Form</span></p><p><b>condition</b>: <span title="Codes: {http://snomed.info/sct 26929004}">Alzheimer's Disease (Disorder)</span>, <span title="Codes: {http://snomed.info/sct G30}">Alzheimer's disease</span>, <span title="Codes: {http://snomed.info/sct 10001896}">Alzheimer's disease</span></p><p><b>contact</b>: Bob James, Ph.D.: ph: 555-555-5555(WORK)</p><h3>RelatedArtifacts</h3><table class="grid"><tr><td>-</td></tr><tr><td>*</td></tr></table><p><b>keyword</b>: <span title="Codes: {https://id.nlm.nih.gov/mesh D018721}">Selective M1 muscarinic agonists</span></p><p><b>description</b>: # Xanomeline (LY246708)
# Protocol H2Q-MC-LZZT(c) 
Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease</p><p><b>sponsor</b>: <a href="Organization-EliLillyAndCompany.html">Generated Summary: id: Eli Lilly and Company (OFFICIAL); <span title="Codes: ">crs</span></a></p><p><b>principalInvestigator</b>: <a href="Practitioner-SamGetWell.html">Generated Summary: UPIN: ABC123 (OFFICIAL); active; Samuel Home ; Phone: 555-123-5467; gender: male</a></p><blockquote><p><b>arm</b></p><p><b>name</b>: Placebo</p><p><b>type</b>: <span title="Codes: {http://ncimeta.nci.nih.gov C49648}">C49648</span></p><p><b>description</b>: Placebo arm</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Low-dose xanomeline arm</p><p><b>type</b>: <span title="Codes: {http://ncimeta.nci.nih.gov C174266}">C174266</span></p><p><b>description</b>: Low-dose xanomeline arm (50 cm2 TTS Formulation E, 54 mg xanomeline)</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: High-dose xanomeline arm</p><p><b>type</b>: <span title="Codes: {http://ncimeta.nci.nih.gov C174266}">C174266</span></p><p><b>description</b>: High-dose xanomeline arm (75 cm2 TTS Formulation E, 81 mg xanomeline)</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To determine if there is a statistically significant relationship (overall Type 1 error rate, α=.05) between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).</p><p><b>type</b>: <span title="Codes: ">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To document the safety profile of the xanomeline TTS.</p><p><b>type</b>: <span title="Codes: ">primary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.</p><p><b>type</b>: <span title="Codes: ">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.</p><p><b>type</b>: <span title="Codes: ">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer’s Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment.</p><p><b>type</b>: <span title="Codes: ">secondary</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: To assess the treatment response as a function of Apo E genotype.</p><p><b>type</b>: <span title="Codes: ">secondary</span></p></blockquote></div>
  </text>
  <identifier>
    <use value="usual"/>
    <value value="H2Q-MC-LZZT"/>
  </identifier>
  <identifier>
    <use value="official"/>
    <system value="https://clinicaltrials.gov/show/"/>
    <value value="NCTA12313212"/>
  </identifier>
  <identifier>
    <use value="secondary"/>
    <type>
      <coding>
        <code value="PLAC"/>
      </coding>
    </type>
    <value value="NCTA12313212"/>
  </identifier>
  <title value="Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer&#x2019;s Disease"/>
  <protocol>
    <reference value="PlanDefinition/LZZT-Study-Definition"/>
  </protocol>
  <status value="completed"/>
  <primaryPurposeType>
    <coding>
      <code value="treatment"/>
    </coding>
  </primaryPurposeType>
  <phase>
    <coding>
      <code value="phase-3"/>
    </coding>
  </phase>
  <category>
    <coding>
      <system value="http://ncimeta.nci.nih.gov"/>
      <code value="C98388"/>
      <display value="Interventional Study"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://ncimeta.nci.nih.gov"/>
      <code value="C15417"/>
      <display value="Randomized Clinical Trial"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://ncimeta.nci.nih.gov"/>
      <code value="C15228"/>
      <display value="Double Blind Study"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://ncimeta.nci.nih.gov"/>
      <code value="C49648"/>
      <display value="Placebo Control"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://ncimeta.nci.nih.gov"/>
      <code value="C82639"/>
      <display value="Parallel Study"/>
    </coding>
  </category>
  <focus>
    <coding>
      <system value="http://ncimeta.nci.nih.gov"/>
      <code value="C152926"/>
      <display value="Xanomeline"/>
    </coding>
  </focus>
  <focus>
    <coding>
      <system value="http://ncimeta.nci.nih.gov"/>
      <code value="C149996"/>
      <display value="Transdermal Patch Dosage Form"/>
    </coding>
  </focus>
  <condition>
    <coding>
      <system value="http://snomed.info/sct"/>
      <code value="26929004"/>
      <display value="Alzheimer&#39;s Disease (Disorder)"/>
    </coding>
  </condition>
  <condition>
    <coding>
      <system value="http://snomed.info/sct"/>
      <code value="G30"/>
      <display value="Alzheimer&#39;s disease"/>
    </coding>
  </condition>
  <condition>
    <coding>
      <system value="http://snomed.info/sct"/>
      <code value="10001896"/>
      <display value="Alzheimer&#39;s disease"/>
    </coding>
  </condition>
  <contact>
    <name value="Bob James, Ph.D."/>
    <telecom>
      <system value="phone"/>
      <value value="555-555-5555"/>
      <use value="work"/>
    </telecom>
  </contact>
  <relatedArtifact>
    <type value="documentation"/>
    <label value="Protocol H2Q-MC-LZZT(c)"/>
    <url value="https://clinicaltrials.gov/show/NCTA12313212/Lzzt_protocol_redacted.pdf"/>
  </relatedArtifact>
  <keyword>
    <coding>
      <system value="https://id.nlm.nih.gov/mesh"/>
      <code value="D018721"/>
    </coding>
    <text value="Selective M1 muscarinic agonists"/>
  </keyword>
  <description value="# Xanomeline (LY246708)&#xA;# Protocol H2Q-MC-LZZT(c) &#xA;Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer&#x2019;s Disease"/>
  <sponsor>
    <reference value="Organization/EliLillyAndCompany"/>
  </sponsor>
  <principalInvestigator>
    <reference value="Practitioner/SamGetWell"/>
  </principalInvestigator>
  <arm>
    <name value="Placebo"/>
    <type>
      <coding>
        <system value="http://ncimeta.nci.nih.gov"/>
        <code value="C49648"/>
      </coding>
    </type>
    <description value="Placebo arm"/>
  </arm>
  <arm>
    <name value="Low-dose xanomeline arm"/>
    <type>
      <coding>
        <system value="http://ncimeta.nci.nih.gov"/>
        <code value="C174266"/>
      </coding>
    </type>
    <description value="Low-dose xanomeline arm (50 cm2 TTS Formulation E, 54 mg xanomeline)"/>
  </arm>
  <arm>
    <name value="High-dose xanomeline arm"/>
    <type>
      <coding>
        <system value="http://ncimeta.nci.nih.gov"/>
        <code value="C174266"/>
      </coding>
    </type>
    <description value="High-dose xanomeline arm (75 cm2 TTS Formulation E, 81 mg xanomeline)"/>
  </arm>
  <objective>
    <name value="To determine if there is a statistically significant relationship (overall Type 1 error rate, &#x3B1;=.05) between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])."/>
    <type>
      <coding>
        <code value="primary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="To document the safety profile of the xanomeline TTS."/>
    <type>
      <coding>
        <code value="primary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas."/>
    <type>
      <coding>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas."/>
    <type>
      <coding>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer&#x2019;s Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment."/>
    <type>
      <coding>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="To assess the treatment response as a function of Apo E genotype."/>
    <type>
      <coding>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
</ResearchStudy>